Search

• Novel iterative CBCT calculated using machine log file in prostate cancer was analyzed. • HU values were uniform at central position in iterative CBCT, and not in conventional CBCT. • Iterative CBCT was consistent with conventional CBCT in accuracy of dose verification. • This method can potentially be used for adaptive radiation therapy. To evaluate the utility of the use of iterative cone-beam computed tomography (CBCT) for machine log file-based dose verification during volumetric modulated arc therapy (VMAT) for prostate cancer patients. All CBCT acquisition data were used to reconstruct images with the Feldkamp-Davis-Kress algorithm (FDK-CBCT) and the novel iterative algorithm (iCBCT). The Hounsfield unit (HU)-electron density curves for CBCT images were created using the Advanced Electron Density Phantom. The I'mRT and anthropomorphic phantoms were irradiated with VMAT after CBCT registration. Subsequently, fourteen prostate cancer patients received VMAT after CBCT registration. Machine log files and both CBCT images were exported to the PerFRACTION software, and a 3D patient dose was reconstructed. Mean dose for planning target volume (PTV), the bladder, and rectum and the 3D gamma analysis were evaluated. For the phantom studies, the variation of HU values was observed at the central position surrounding the bones in FDK-CBCT. There were almost no changes in the difference of doses at the isocenter between measurement and reconstructed dose for planning CT (pCT), FDK-CBCT, and iCBCT. Mean dose differences of PTV, rectum, and bladder between iCBCT and pCT were approximately 2% lower than those between FDK-CBCT and pCT. For the clinical study, average gamma analysis for 2%/2 mm was 98.22% ± 1.07 and 98.81% ± 1.25% in FDK-CBCT and iCBCT, respectively. A similar machine log file-based dose verification accuracy is obtained for FDK-CBCT and iCBCT during VMAT for prostate cancer patients. [ABSTRACT FROM AUTHOR]

• A deep learning model was developed to generate 60 keV VMI from single-energy CT. • Pancreatic tumor imaging quality in 60 keV VMI is superior to SECT. • 60 keV VMI generated from SECT may better support pancreatic tumor treatment planning. To construct a deep convolutional neural network that generates virtual monochromatic images (VMIs) from single-energy computed tomography (SECT) images for improved pancreatic cancer imaging quality. Fifty patients with pancreatic cancer underwent a dual-energy CT simulation and VMIs at 77 and 60 keV were reconstructed. A 2D deep densely connected convolutional neural network was modeled to learn the relationship between the VMIs at 77 (input) and 60 keV (ground-truth). Subsequently, VMIs were generated for 20 patients from SECT images using the trained deep learning model. The contrast-to-noise ratio was significantly improved (p < 0.001) in the generated VMIs (4.1 ± 1.8) compared to the SECT images (2.8 ± 1.1). The mean overall image quality (4.1 ± 0.6) and tumor enhancement (3.6 ± 0.6) in the generated VMIs assessed on a five-point scale were significantly higher (p < 0.001) than that in the SECT images (3.2 ± 0.4 and 2.8 ± 0.4 for overall image quality and tumor enhancement, respectively). The quality of the SECT image was significantly improved both objectively and subjectively using the proposed deep learning model for pancreatic tumors in radiotherapy. [ABSTRACT FROM AUTHOR]

• CT numbers in the low energy VMI can be inaccurate for high density materials. • HU values in the VMI 77keV is less affected by the scanning protocols than 120 kVp image. • The effect of the inaccurate CT numbers on PTV was more prominent in AXB than AAA. • Maximum dosimetric error in VMAT planning based on the VMI 50keV was 0.5 Gy. • The dosimetric error due to the inaccurate HU estimation may be clinically insignificant. Though virtual monochromatic images (VMIs) at low energy levels can improve image quality, the measured Hounsfield unit (HU) values can be inaccurate. We assessed the dosimetric error due to inaccurate HU estimation in volumetric modulated arc therapy (VMAT) planning. Based on the VMIs at 50 keV (VMI 50keV), 77 keV (VMI 77keV) and single-energy CT (SECT) image for a phantom with different sizes, lookup tables (LUT L and LUT S) were created. Using an anthropomorphic phantom (head and spine regions), VMAT plans were generated based on VMI 50keV , VMI 77keV and SECT using the corresponding LUT L , and then, the doses were re-calculated using LUT S. For clinical cases, 30 VMAT plans (prostate, brain, and spine cases) were generated based on VMI 50keV and VMI 77keV. In the anthropomorphic phantom study, the difference in the dosimetric parameters for planning target volume (PTV) in the VMAT plan based on the VMI 77keV was smallest (within 0.1 Gy) among three types of treatment planning approach. In clinical cases, in general, the differences of the 3-dimensional gamma passing rate and dosimetric parameters in the treatment plans based on the VMI 50keV were larger than those in the VMI 77keV. Especially for brain cases, the difference for PTV was more prominent when AXB was used (the maximum difference was 0.5 Gy) than AAA. The dosimetric error due to the inaccurate HU estimation was larger in the VMIs at low energy levels. This may be clinically insignificant, but should be avoided in the VMAT treatment planning. [ABSTRACT FROM AUTHOR]

Highlights • DLCT allows to estimate electron densities and effective atomic number. • DLCT system provided an accuracy to determine electron density (<0.1%). • An accuracy to determine atomic number was varied widely with mean −2.0%. • Stopping power ratio can be estimated with an accuracy of 0.3%. • The accurate measurements could improve dose calculation in radiotherapy treatment. Abstract Purpose Assess the accuracy for quantitative measurements of electron density relative to water (ρ e / ρ e,w), effective atomic number (Z eff) and stopping power ratio relative to water (SPR w) using a dual-layer computed tomography (DLCT) system. Methods and Materials A tissue characterization phantom was scanned using DLCT with varying scanning parameters (i.e., tube voltage, rotation time, CTDI vol , and scanning mode) and different reference materials. Then, electron density ρ e / ρ e,w and atomic number Z eff images were reconstructed, and their values were determined for each reference materials. Based on these two values, SPR w was calculated. Finally, the percent error (PE) against the theoretical values was calculated for reference materials. Results Significant linear relationships (p < 0.001) were observed between the measured and theoretical ρ e / ρ e,w (r = 1.000), Z eff (r = 0.989) and SPR w (r = 1.000) values. The PE for each reference material varied from –2.0 to 1.2% (mean, <0.1%) for electron density ρ e / ρ e,w , from –6.4 to 8.0% (mean, –2.0%) for atomic number Z eff , and from –2.0 to 1.9% (mean, 0.3%) for stopping power ratio SPR w. The mean PE of ρ e / ρ e,w (<0.1%), Z eff (<–2.5%) and SPR w (<0.4%) was verified across the variation of scanning parameters (p > 0.85). Conclusions DLCT provides a reasonable accuracy in the measurements of ρ e / ρ e,w , Z eff and SPR w , and could enhance radiotherapy treatment planning and the subsequent outcomes. [ABSTRACT FROM AUTHOR]

Rationale and Objectives: Because it is imperative for understanding the performance of dual-energy computed tomography scanner to determine clinical diagnosis, we aimed to assess the accuracy of quantitative measurements using dual-energy computed tomography with fast kilovoltage switching.Materials and Methods: Quantitative measurements were performed for 16 reference materials (physical density, 0.965-1.550 g/cm3; diameter of rod, 2.0-28.5 mm; iodine concentration, 2-15 mg/mL; and calcium concentration, 50-300 mg/mL) with varying scanning settings, and the measured values were compared to their theoretical values.Results: For high-density material, the maximum differences in Hounsfield unit values in the virtual monochromatic images at 50, 70, and 100 keV were -176.2, 61.0, and -35.2 HU, respectively, and the standard deviations over short- and long-term periods were 11.1, 6.1, and 3.5 HU at maximum. The accuracy of the Hounsfield unit measurement at 50 and 70 keV was significantly higher (P < 0.05) with higher radiation output and smaller phantom size. The difference in the iodine and calcium measurements in the large phantom were up to -2.6 and -60.4 mg/mL for iodine (5 mg/mL with 2-mm diameter) and calcium (300 mg/mL) materials, and the difference was improved with a small phantom. Metal artifact reduction software improved subjective image quality; however, the quantitative values were significantly underestimated (P < 0.05) (-49.5, -26.9, and -15.3 HU for 50, 70, and 100 keV, respectively; -1.0 and -17 mg/mL for iodine and calcium concentration, respectively) compared to that acquired without a metal material.Conclusions: The accuracy of quantitative measurements can be affected by material density and the size of the object, radiation output, phantom size, and the presence of metal materials. [ABSTRACT FROM AUTHOR]

Purpose: Megavoltage cone beam computed tomography (MV-CBCT) dose can be integrated with the patient’s prescription. Here, we investigated the effects of imaging dose and the necessity for additional optimization when using intensity-modulated radiotherapy (IMRT) to treat prostate cancer. Methods and Materials: An arc beam mimicking MV-CBCT was generated using XiO (version 4.50; Elekta, Stockholm, Sweden). The monitor units (MU) for dose calculation were determined by conforming the calculated dose to the dose measured using an ionization chamber. IMRT treatment plans of 22 patients with prostate cancer were retrospectively analyzed. Arc beams of 3, 5, 8, and 15 MU were added to the IMRT plans, and the dose covering 95% of the planning target volume (PTV) was normalized to the prescribed dose with (reoptimization) or without optimization (compensation). Results: PTV homogeneity and conformality changed negligibly with MV-CBCT integration. For critical organs, an imaging dose-dependent increase was observed for the mean rectal/bladder dose (D mean), and reoptimization effectively suppressed the D mean elevations. The bladder generalized equivalent uniform dose (gEUD) increased with imaging dose, and reoptimization suppressed the gEUD elevation when 5- to 15-MU CBCT were added, although rectal gEUD changed negligibly with any imaging dose. Whereas the dose elevation from the simple addition of the imaging dose uniformly increased rectal and bladder dose, the rectal D mean increase of compensation plans was due mainly to low-dose volumes. In contrast, bladder high-dose volumes were increased by integrating the CBCT dose, and reoptimization reduced them when 5- to 15-MU CBCT were added. Conclusion: Reoptimization is clearly beneficial for reducing dose to critical organs, elevated by addition of high-MU CBCT, especially for the bladder. For low-MU CBCT aimed at bony structure visualization, compensation is sufficient. [ABSTRACT FROM AUTHOR]

Abstract: A linac manufacturer has recommended that users measure virtual wedge (VW) angle and VW factor as a weekly quality assurance (QA) procedure. The purpose of this study was to investigate whether a 2D diode detector array (MapCHECK™) is a useful tool for the verification of dosimetric data for VW. Measurements were performed on 2 linear accelerators (4, 6, and 10 MV) at 10-cm depth for a field size of 10 × 10 cm2 and with wedge angles of 15, 30, 45, and 60°. To verify the VW dose distributions generated by the treatment planning system (TPS), we confirmed that agreement between TPS data and measurements were ≤2% dose difference or 2-mm distance-to-agreement based on American Association of Physicists in Medicine Task Group Report 53 (AAPM TG-53). We present here the results of a 1-year evaluation of VW by means of a 2D diode detector array. The maximum 2-fold standard deviation of the measured wedge angle turned out to be within 1.0, and all measured VW factors to be 1.00 ± 0.03. Although >95% of the points measured for 6 and 10 MV were generally within the tolerance of the dose distribution as mentioned above, the percentage of agreement between the measured data for 4 MV and TPS data were somewhat below 90%. We also verified generally good reproducibility for the dose distribution. The 2-D diode detector array was thus found to be useful as a tool for weekly VW QA. [Copyright &y& Elsevier]

Purpose: To perform the largest in vivo dosimetry study for interstitial brachytherapy yet to be undertaken using a new radiophotoluminescence glass dosimeter (RPLGD) in patients with pelvic malignancy and to study the limits of contemporary planning software based on the results. Patients and Methods: Sixty-six patients with pelvic malignancy were treated with high-dose-rate interstitial brachytherapy, including prostate (n = 26), gynecological (n = 35), and miscellaneous (n = 5). Doses for a total of 1004 points were measured by RPLGDs and calculated with planning software in the following locations: rectum (n = 549), urethra (n = 415), vagina (n = 25), and perineum (n = 15). Compatibility (measured dose/calculated dose) was analyzed according to dosimeter location. Results: The compatibility for all dosimeters was 0.98 ± 0.23, stratified by location: rectum, 0.99 ± 0.20; urethra, 0.96 ± 0.26; vagina, 0.91 ± 0.08; and perineum, 1.25 ± 0.32. Conclusions: Deviations between measured and calculated doses for the rectum and urethra were greater than 20%, which is attributable to the independent movements of these organs and the applicators. Missing corrections for inhomogeneity are responsible for the 9% negative shift near the vaginal cylinder (specific gravity = 1.24), whereas neglect of transit dose contributes to the 25% positive shift in the perineal dose. Dose deviation of >20% for nontarget organs should be taken into account in the planning process. Further development of planning software and a real-time dosimetry system are necessary to use the current findings and to achieve adaptive dose delivery. [Copyright &y& Elsevier]

Purpose: The largest in vivo dosimetry study for interstitial brachytherapy yet examined was performed using new radiophotoluminescence glass dosimeters (RPLGDs). Based on the results, a dose prescription technique achieving high reproducibility and eliminating large hyperdose sleeves was studied. Methods and materials: For 61 head-and-neck cancer patients who underwent high-dose-rate interstitial brachytherapy, new RPLGDs were used for an in vivo study. The Paris System was used for implant. An arbitrary isodose surface was selected for dose prescription. Locations of 83 dosimeters were categorized as on target (n = 52) or on nontarget organ (n = 31) and were also scaled according to % basal dose isodose surface (% BDIS). Compatibility (measured dose/calculated dose) was analyzed according to location. The hyperdose sleeve was assessed in terms of prescription surface expressed in % BDIS. Results: The spread of compatibilities was larger for on nontarget organ (1.06 ± 0.32) than for on target (0.87 ± 0.17, p = 0.01). Within on target RPLGDs, compatibility on <95% BDIS (0.95 ± 0.10) was better than on ≥95% BDIS (0.84 ± 0.18, p = 0.02). The number of patients with diameter of hyperdose sleeve ≥10 mm was increased with a dose prescription to <77% BDIS (p = 0.046). For nontarget organs, the maximal positive deviation was 84% of the calculated dose. Conclusions: Dose prescription is recommended to >77% and <95% BDIS for reproducibility and elimination of excessive hyperdose sleeve. For organs at risk, radioprotection should be considered even when calculated dose seems sufficiently low. Further development of planning software is necessary to prevent overestimation. [Copyright &y& Elsevier]

Purpose: Low-dose-rate interstitial brachytherapy (LDRIB) represents an effective modality for treatment of oropharyngeal carcinoma. The drawback is radioexposure of medical personnel. To eliminate this concern, we initiated high-dose-rate interstitial brachytherapy (HDRIB) in 1993. The present study evaluated the efficacy and complications associated with this approach.Methods and materials: Between 1993 and 2003, HDRIB ± external radiotherapy was used to treat 83 oropharyngeal squamous cell carcinomas. Median duration of follow-up was 26 months (range, 1–108 months). Of the 82 patients, 76 were previously untreated and 6 displayed previous history of head and neck cancer. T distribution comprised T1 (n = 7), T2 (n = 47), T3 (n = 24), and T4a (n = 5). External radiotherapy of 46 Gy was combined with 21 Gy/3.5 fractions/2 days HDRIB for 68 lesions, and 48 Gy/8 fractions/5 days HDRIB alone was used for 15 lesions. Involved nodes were either boosted by external radiotherapy or resected.Results: Five-year local control, regional control, cause-specific and overall survival rates were 82%, 84%, 88%, and 64%, respectively. Local control rates for early (T1/T2) and advanced (T3/T4) tumors were 89% and 66%, respectively (p = 0.02). Transient soft tissue necrosis was experienced in 29% of patients. No bone sequelae were observed in previously untreated patients.Conclusions: High-dose-rate interstitial brachytherapy could achieve excellent local control and acceptable rates of complication, equivalent to reported results for LDRIB series. Given the advantage of radioprotection, HDRIB may replace LDRIB in the treatment of oropharyngeal carcinoma. [Copyright &y& Elsevier]

This study aimed to compare dosimetric parameters for targets and organs at risk (OARs) between volumetric modulated arc therapy (VMAT) and automated VMAT (HyperArc, HA) plans in stereotactic radiotherapy for patients with cervical metastatic spine tumors. VMAT plans were generated for 11 metastases using the simultaneous integrated boost technique to deliver 35 to 40 and 20 to 25 Gy for high dose and elective dose planning target volume (PTVHD and PTVED), respectively. The HA plans were retrospectively generated using 1 coplanar and 2 noncoplanar arcs. Subsequently, the doses to the targets and OARs were compared. The HA plans provided significantly higher (p < 0.05) D min (77.4 ± 13.1%), D 99% (89.3 ± 8.9%), and D 98% (92.5 ± 7.7%) for gross tumor volume (GTV) than those of the VMAT plans (73.4 ± 12.2%, 84.2 ± 9.6 and 87.3 ± 8.8% for D min , D 99% and D 98% , respectively). In addition, D 99% and D 98% for PTVHD were significantly higher in the HA plans, whereas dosimetric parameters were comparable between the HA and VMAT plans for PTVED. The D max values for the brachial plexus, esophagus, and spinal cord were comparable, and no significant difference was observed in the D mean for the larynx, pharyngeal constrictor, thyroid, parotid grand (left and right), and Submandibular gland (left and right). The HA plans provided significantly higher target coverage of GTV and PTVHD, with a comparable dose for OARs with VMAT plans. The results of this study may contribute to the improvement of local control in clinical practice. [ABSTRACT FROM AUTHOR]

To compare dosimetric parameters for the hippocampus, organs at risk (OARs), and targets of volumetric modulated arc therapy (VMAT), noncoplanar VMAT (NC-VMAT), and HyperArc (HA) plans in patients undergoing postoperative radiotherapy for primary brain tumors. For 20 patients, HA plans were generated to deliver 40.05 to 60 Gy for the planning target volume (PTV). In addition, doses for the hippocampus and OARs were minimized. The VMAT and NC-VMAT plans were retrospectively generated using the same optimization parameters as those in the HA plans. For the hippocampus, the equivalent dose to be administered in 2 Gy fractions (EQD 2) was calculated assuming α/β = 2. Dosimetric parameters for the PTV, hippocampus, and OARs in the VMAT, NC-VMAT, and HA plans were compared. For PTV, the HA plans provided significantly lower D max and D 1% than the VMAT and NC-VMAT plans (p < 0.05), whereas the D 99% and D min were significantly higher (p < 0.05). For the contralateral hippocampus, the dosimetric parameters in the HA plans (8.1 ± 9.6, 6.5 ± 7.2, 5.6 ± 5.8, and 4.8 ± 4.7 Gy for D 20% , D 40% , D 60% and D 80% , respectively) were significantly smaller (p < 0.05) than those in the VMAT and NC-VMAT plans. Except for the optic chiasm, the D max in the HA plans (brainstem, lens, optic nerves, and retinas) was the smallest (p < 0.05). In addition, the doses in the HA plans for the brain and skin were the smallest (p < 0.05) among the 3 plans. HA planning, instead of coplanar and noncoplanar VMAT, significantly reduces the dosage to which the contralateral hippocampus as well as other OARs are exposed without compromising on target coverage. [ABSTRACT FROM AUTHOR]

Accurate clinical target volume (CTV) delineation is important for head and neck intensity-modulated radiation therapy. However, delineation is time-consuming and susceptible to interobserver variability (IOV). Based on a manual contouring process commonly used in clinical practice, we developed a deep learning (DL)-based method to delineate a low-risk CTV with computed tomography (CT) and gross tumor volume (GTV) input and compared it with a CT-only input. A total of 310 patients with oropharynx cancer were randomly divided into the training set (250) and test set (60). The low-risk CTV and primary GTV contours were used to generate label data for the input and ground truth. A 3D U-Net with a two-channel input of CT and GTV (U-Net GTV) was proposed and its performance was compared with a U-Net with only CT input (U-Net CT). The Dice similarity coefficient (DSC) and average Hausdorff distance (AHD) were evaluated. The time required to predict the CTV was 0.86 s per patient. U-Net GTV showed a significantly higher mean DSC value than U-Net CT (0.80 ± 0.03 and 0.76 ± 0.05) and a significantly lower mean AHD value (3.0 ± 0.5 mm vs 3.5 ± 0.7 mm). Compared to the existing DL method with only CT input, the proposed GTV-based segmentation using DL showed a more precise low-risk CTV segmentation for head and neck cancer. Our findings suggest that the proposed method could reduce the contouring time of a low-risk CTV, allowing the standardization of target delineations for head and neck cancer. [ABSTRACT FROM AUTHOR]

Purpose: The purpose of this study was to reconfirm our previous findings that the rectal dose and source strength both affect late rectal bleeding after high-dose-rate intracavitary brachytherapy (HDR-ICBT), by using a rectal dose calculated in accordance with the definitions of the International Commission on Radiation Units and Measurements Report 38 (ICRURP) or of dose–volume histogram (DVH) parameters by the Groupe Européen de Curietherapie of the European Society for Therapeutic Radiology and Oncology. Methods and Materials: Sixty-two patients who underwent HDR-ICBT and were followed up for 1 year or more were studied. The rectal dose for ICBT was calculated by using the ICRPRP based on orthogonal radiographs or the DVH parameters based on computed tomography (CT). The total dose was calculated as the biologically equivalent dose expressed in 2-Gy fractions (EQD2). The relationship between averaged source strength or the EQD2 and late rectal bleeding was then analyzed. Results: When patients were divided into four groups according to rectal EQD2 (≥ or

Abstract: Purpose: The aim of the study was to evaluate the results of high-dose-rate interstitial brachytherapy (HDR-ISBT) for patients with advanced cervical carcinoma in which intracavitary radiation therapy may result in a suboptimal dose distribution. Methods and Materials: Between 1995 and 2005, 25 patients of median age 64 years were treated with external beam radiation therapy and HDR-ISBT. The International Federation of Gynecology and Obstetrics stages of the patients were I (4%), II (16%), III (68%), and IVA (12%). Whole pelvic irradiation of 30Gy/15 fractions was followed by HDR-ISBT of 30Gy/5 fractions/3 days. Subsequently, additional pelvic external beam radiation therapy of 20Gy/10 fractions was delivered with a midline block. The median followup period was 55 months. Results: The actuarial 5-year progression-free survival and overall survival rates for all cases were 42% and 54%, respectively. For the 17 patients with a Stage III tumor, the 5-year local control and overall survival rates were 73% and 51%, respectively. Two patients (8%) developed late toxicities of Grade 3. Conclusions: A high rate of pelvic control and survival with acceptable level of late toxicities were obtained for patients with advanced cervical carcinoma treated with HDR-ISBT. [Copyright &y& Elsevier]

To compare the effect of a contrast-enhanced (CE) agent on volumetric-modulated arc therapy plans based on four types of images—virtual monochromatic images (VMIs) captured at 70 and 140 keV (namely VMI 70 and VMI 140 , respectively), water density image (WDI), and virtual non-contrast image (VNC) generated using a dual-energy computed tomography (DECT) system. A tissue characterization phantom and a multi-energy phantom were scanned, and VMI 70 , VMI 140 , WDI, and VNC were retrospectively reconstructed. For each image, a lookup table (LUT) was created. For 13 patients with nasopharyngeal cancer, non-CE and CE scans were performed, and volumetric-modulated arc therapy plans were generated on the basis of non-CE VMI 70. Subsequently, the doses were re-calculated using the four types of DECT images and their corresponding LUTs. The maximum differences in the physical density estimation were 21.3, 5.2, −3.9, and 0.5% for VMI 70 , VMI 140 , WDI, and VNC, respectively. Compared with VMI 70 , the WDI approach significantly reduced (p < 0.05) the dosimetric difference due to the CE agent for the planning target volume (PTV) (D 50%), whereas the difference was significantly increased for D 1%. Except for PTV (D 1%), the differences were significantly lower (p < 0.05) in the treatment plans based on VMI 140 and VNC than that based on VMI 70. For the VNC, the mean difference was less than 0.2% for all dosimetric parameters for the PTV. For patients with NPC, treatment plans based on the VNC derived from CE scan showed the best agreement with those based on the non-CE VMI 70. Ideally, the effect of CE agent on dose distribution does not appear in treatment planning procedures. [ABSTRACT FROM AUTHOR]

We performed a dosimetric study to evaluate the benefits of using a flattening-filter-free (FFF) beam with the deep inspiration breath-hold (DIBH) method for left-breast cancer. We used data from 30 previous patients with treatment plans that included DIBH for left-breast cancer with a flattened beam. FFF beam plans were calculated from previous treatment plan images and compared to the original plans in terms of monitor units (MU), number of segments, beam-on time, and breath-holds. Beam-on time was calculated by adding the traveling time of 1.5 second between segments to the time calculated from the MU and dose rate. Breath-holds were calculated based on the beam-on time, assuming 15 s per hold. The FFF beam had increased MU in all cases (mean ± SD: flattened beam, 122.4 ± 9.8 MU; FFF beam, 160.2 ± 17.5 MU). Furthermore, the number of segments increased with the FFF beam in all cases (median [range]: flattened beam, 2 [1 to 3]; FFF beam, 5 [3 to 7]). However, in most cases, the beam-on time was reduced using the FFF beam (mean ± SD: flattened beam, 27.8 ± 7.4 seconds; FFF beam, 13.2 ± 1.7 seconds), although when a 6 MV flattened beam was used there was not a large increase. There were fewer breath-holds in most cases with the FFF beam. Cases using a 4 MV flattened beam also had fewer breath-holds; however, the number of breath-holds was consistent or increased in cases that used a 6 MV flattened beam (median [range]: flattened beam, 3 [1 to 3]; FFF beam, 1 [1 to 2]). [ABSTRACT FROM AUTHOR]

We assessed the effect of collimator angle on the dosimetric parameters for targets and organs at risk (OARs) for collimator-optimized HA (CO-HA) and non-CO-HA (nCO-HA) plans. The nCO-HA and CO-HA plans were retrospectively generated for 26 patients (1 to 8 brain metastases). The dosimetric parameters for planning target volume (homogeneity index [HI]; conformity index [CI]; gradient index [GI]) and for OARs were compared. The modulation complexity score for volumetric modulated arc therapy (MCSV) and monitor units (MUs) were calculated. Doses were measured using the electronic portal imaging device and compared with the expected doses. Dosimetric parameters of the HI, CI, and GI for single (n = 12) and multiple (n = 14) metastases cases were comparable (p > 0.05). For multiple metastases cases, the CO-HA plan provided lower V 4Gy , V 12Gy , V 14Gy , V 16Gy for brain tissue compared to the nCO-HA plan (p < 0.05). Doses for OARs (D 0.1cc) (brainstem, chiasm, Hippocampus, lens, optic nerves, and retinas) were comparable (p > 0.05). For multiple metastases cases, the CO-HA plan resulted in less complex multileaf collimator (MLC) patterns (MCSV = 0.19 ± 0.04, p < 0.01), lower MUs (8596 ± 1390 MUs, p < 0.01), and shorter beam-on time (6.2 ± 1.0 min, p < 0.01) compared to the nCO-HA plan (0.16 ± 0.04, 9365 ± 1630, and 6.7 ± 1.2 for MCSV, MUs, and beam-on time, respectively). For both treatment approach, the equivalent gamma passing rate was obtained with the 3%/3 mm and 2%/2 mm criteria (p > 0.05). The collimator optimization in the HA planning reduced doses to brain tissues and improved the treatment efficacy. [ABSTRACT FROM AUTHOR]

Purpose: To investigate the impact of setup and range uncertainties, breathing motion, and interplay effects using scanning pencil beams in robustly optimized intensity modulated proton therapy (IMPT) for stage III non-small cell lung cancer (NSCLC).Methods and Materials: Three-field IMPT plans were created using a minimax robust optimization technique for 10 NSCLC patients. The plans accounted for 5- or 7-mm setup errors with ±3% range uncertainties. The robustness of the IMPT nominal plans was evaluated considering (1) isotropic 5-mm setup errors with ±3% range uncertainties; (2) breathing motion; (3) interplay effects; and (4) a combination of items 1 and 2. The plans were calculated using 4-dimensional and average intensity projection computed tomography images. The target coverage (TC, volume receiving 95% of prescribed dose) and homogeneity index (D2 - D98, where D2 and D98 are the least doses received by 2% and 98% of the volume) for the internal clinical target volume, and dose indexes for lung, esophagus, heart and spinal cord were compared with that of clinical volumetric modulated arc therapy plans.Results: The TC and homogeneity index for all plans were within clinical limits when considering the breathing motion and interplay effects independently. The setup and range uncertainties had a larger effect when considering their combined effect. The TC decreased to <98% (clinical threshold) in 3 of 10 patients for robust 5-mm evaluations. However, the TC remained >98% for robust 7-mm evaluations for all patients. The organ at risk dose parameters did not significantly vary between the respective robust 5-mm and robust 7-mm evaluations for the 4 error types. Compared with the volumetric modulated arc therapy plans, the IMPT plans showed better target homogeneity and mean lung and heart dose parameters reduced by about 40% and 60%, respectively.Conclusions: In robustly optimized IMPT for stage III NSCLC, the setup and range uncertainties, breathing motion, and interplay effects have limited impact on target coverage, dose homogeneity, and organ-at-risk dose parameters. [ABSTRACT FROM AUTHOR]

There are 2 methods commonly used for patient positioning in the anterior-posterior (A-P) direction: one is the skin mark patient setup method (SMPS) and the other is the couch height–based patient setup method (CHPS). This study compared the setup accuracy of these 2 methods for abdominal radiation therapy. The enrollment for this study comprised 23 patients with pancreatic cancer. For treatments (539 sessions), patients were set up by using isocenter skin marks and thereafter treatment couch was shifted so that the distance between the isocenter and the upper side of the treatment couch was equal to that indicated on the computed tomographic (CT) image. Setup deviation in the A-P direction for CHPS was measured by matching the spine of the digitally reconstructed radiograph (DRR) of a lateral beam at simulation with that of the corresponding time-integrated electronic portal image. For SMPS with no correction (SMPS/NC), setup deviation was calculated based on the couch-level difference between SMPS and CHPS. SMPS/NC was corrected using 2 off-line correction protocols: no action level (SMPS/NAL) and extended NAL (SMPS/eNAL) protocols. Margins to compensate for deviations were calculated using the Stroom formula. A-P deviation > 5 mm was observed in 17% of SMPS/NC, 4% of SMPS/NAL, and 4% of SMPS/eNAL sessions but only in one CHPS session. For SMPS/NC, 7 patients (30%) showed deviations at an increasing rate of > 0.1 mm/fraction, but for CHPS, no such trend was observed. The standard deviations (SDs) of systematic error (Σ) were 2.6, 1.4, 0.6, and 0.8 mm and the root mean squares of random error (σ) were 2.1, 2.6, 2.7, and 0.9 mm for SMPS/NC, SMPS/NAL, SMPS/eNAL, and CHPS, respectively. Margins to compensate for the deviations were wide for SMPS/NC (6.7 mm), smaller for SMPS/NAL (4.6 mm) and SMPS/eNAL (3.1 mm), and smallest for CHPS (2.2 mm). Achieving better setup with smaller margins, CHPS appears to be a reproducible method for abdominal patient setup. [ABSTRACT FROM AUTHOR]

Abstract: Purpose: To report preliminary results of our second regimen with 45.5Gy/7 fractions aiming to reduce toxicity, compared with our first regimen with 54Gy/9 fractions, using high-dose-rate (HDR) brachytherapy as monotherapy for prostate cancer. Materials and methods: From 2005 through 2010, 63 patients with localized prostate cancer were treated with HDR brachytherapy alone in 45.5Gy/7 fractions for 4days. Thirty-four patients were considered as intermediate-risk and 29 as high-risk. Thirty-seven patients also received neoadjuvant and/or adjuvant hormonal therapy. Biologically effective dose assuming α/β =1.5Gy (BED1.5) was reduced from 270Gy to 243Gy, and BED3.0 from 162Gy to 144Gy, compared to previous 54Gy/9 fractions for 5days. Results: Median follow-up time was 42months (range 13–72). Grade 2 acute toxicities occurred in six (9.5%), late toxicities in five (7.9%) patients, and Grade 3 or higher in none. Grade 2 late gastrointestinal toxicity rate was 1.6%, compared with 7.1% for the 54Gy regimen. Three-year PSA failure-free rates for intermediate- and high-risk patients were 96% and 90%, which were comparable to 93% and 85% for the 54Gy regimen. Conclusions: Compared to the 54 Gy/9 fractions regimen, dose-reduced regimen of 45.5Gy/7 fractions using HDR brachytherapy as monotherapy preliminarily showed an equivalent or lower incidence rate for acute and late toxicities without compromising the excellent PSA failure-free rate. Further studies with more patients and longer follow-up are warranted. [Copyright &y& Elsevier]

Purpose: The purpose of this study was to evaluate dose-volume histogram (DVH) predictors for the development of chronic gastrointestinal (GI) complications in cervical cancer patients who underwent radical hysterectomy and postoperative concurrent nedaplatin-based chemoradiation therapy. Methods and Materials: This study analyzed 97 patients who underwent postoperative concurrent chemoradiation therapy. The organs at risk that were contoured were the small bowel loops, large bowel loop, and peritoneal cavity. DVH parameters subjected to analysis included the volumes of these organs receiving more than 15, 30, 40, and 45 Gy (V15-V45) and their mean dose. Associations between DVH parameters or clinical factors and the incidence of grade 2 or higher chronic GI complications were evaluated. Results: Of the clinical factors, smoking and low body mass index (BMI) (<22) were significantly associated with grade 2 or higher chronic GI complications. Also, patients with chronic GI complications had significantly greater V15-V45 volumes and higher mean dose of the small bowel loops compared with those without GI complications. In contrast, no parameters for the large bowel loop or peritoneal cavity were significantly associated with GI complications. Results of the receiver operating characteristics (ROC) curve analysis led to the conclusion that V15-V45 of the small bowel loops has high accuracy for prediction of GI complications. Among these parameters, V40 gave the highest area under the ROC curve. Finally, multivariate analysis was performed with V40 of the small bowel loops and 2 other clinical parameters that were judged to be potential risk factors for chronic GI complications: BMI and smoking. Of these 3 parameters, V40 of the small bowel loops and smoking emerged as independent predictors of chronic GI complications. Conclusions: DVH parameters of the small bowel loops may serve as predictors of grade 2 or higher chronic GI complications after postoperative concurrent nedaplatin-based chemoradiation therapy for early-stage cervical cancer. [Copyright &y& Elsevier]

Purpose: To delineate changing trends in radical external beam radiotherapy (EBRT) for prostate cancer in Japan. Methods and Materials: Data from 841 patients with clinically localized prostate cancer treated with EBRT in the Japanese Patterns of Care Study (PCS) from 1996 to 2005 were analyzed. Results: Significant increases in the proportions of patients with stage T1 to T2 disease and decrease in prostate-specific antigen values were observed. Also, there were significant increases in the percentages of patients treated with radiotherapy by their own choice. Median radiation doses were 65.0 Gy and 68.4 Gy from 1996 to 1998 and from 1999 to 2001, respectively, increasing to 70 Gy from 2003 to 2005. Moreover, conformal therapy was more frequently used from 2003 to 2005 (84.9%) than from 1996 to 1998 (49.1%) and from 1999 to 2001 (50.2%). On the other hand, the percentage of patients receiving hormone therapy from 2003 to 2005 (81.1%) was almost the same as that from 1996 to 1998 (86.3%) and from 1999 to 2001 (89.7%). Compared with the PCS in the United States, patient characteristics and patterns of treatments from 2003 to 2005 have become more similar to those in the United States than those from 1996 to 1998 and those from 1999 to 2001. Conclusions: This study indicates a trend toward increasing numbers of patients with early-stage disease and increasing proportions of patients treated with higher radiation doses with advanced equipment among Japanese prostate cancer patients treated with EBRT during 1996 to 2005 survey periods. Patterns of care for prostate cancer in Japan are becoming more similar to those in the United States. [Copyright &y& Elsevier]

Purpose: To evaluate an extreme hypofractionation regimen with 54 Gy in nine fractions provided by high-dose-rate (HDR) brachytherapy as monotherapy for prostate cancer by reporting 5-year clinical results. Methods and Materials: Between 1996 and 2005, 112 patients with localized prostate cancer were treated with HDR brachytherapy without external beam radiotherapy. Of the 112 patients, 15 were considered low risk, 29 intermediate risk, and 68 as high risk. The prescribed dose was uniformly 54 Gy in nine fractions within 5 days. Of the 112 patients, 94 also received hormonal therapy. The median follow-up time was 5.4 years. Results: All the patients safely completed the treatment regimen. The 5-year prostate-specific antigen (PSA) failure-free, local control, disease-free survival, and overall survival rate was 83%, 97%, 87%, and 96%, respectively. The 5-year PSA failure-free rate for low-, intermediate-, and high-risk patients was 85% (95% confidence interval, 66–100%), 93% (95% confidence interval, 83–100%), and 79% (95% confidence interval, 69–89%), respectively. The significant prognostic factors for PSA failure were the initial PSA level (p = .029) and younger age (p = .019). The maximal toxicities observed were Grade 3 using the Common Terminology Criteria for Adverse Events, version 3.0, for both acute and late toxicity (6 and 3 patients had acute and late Grade 3 toxicity, respectively). Late Grade 2 toxicity was observed in 13 patients. Conclusion: Monotherapeutic HDR brachytherapy with an extreme hypofractionation regimen of 54 Gy in nine fractions associated with hormonal therapy was feasible, and its toxicity was acceptable. The interim tumor control rate at a median 5.4 years was promising, even for patients with locally advanced disease. This dose-fractionation scheme might be referred to by other terms, such as stereotactic body radiotherapy. Studies with longer follow-up periods and from multiple institutions are needed to confirm the efficacy of this novel approach. [Copyright &y& Elsevier]

Purpose: To evaluate the ongoing structure of radiation oncology in Japan in terms of equipment, personnel, patient load, and geographic distribution to identify and improve any deficiencies. Methods and Materials: A questionnaire-based national structure survey was conducted from March to December 2008 by the Japanese Society of Therapeutic Radiology and Oncology (JASTRO). These data were analyzed in terms of the institutional stratification of the Patterns of Care Study. Results: The total numbers of new cancer patients and total cancer patients (new and repeat) treated with radiation in 2007 were estimated at 181,000 and 218,000, respectively. There were 807 linear accelerator, 15 telecobalt, 46 Gamma Knife, 45 60Co remote-controlled after-loading, and 123 192Ir remote-controlled after-loading systems in actual use. The linear accelerator systems used dual-energy function in 539 units (66.8%), three-dimensional conformal radiation therapy in 555 (68.8%), and intensity-modulated radiation therapy in 235 (29.1%). There were 477 JASTRO-certified radiation oncologists, 826.3 full-time equivalent (FTE) radiation oncologists, 68.4 FTE medical physicists, and 1,634 FTE radiation therapists. The number of interstitial radiotherapy (RT) administrations for prostate, stereotactic body radiotherapy, and intensity-modulated radiation therapy increased significantly. Patterns of Care Study stratification can clearly identify the maturity of structures based on their academic nature and caseload. Geographically, the more JASTRO-certified physicians there were in a given area, the more RT tended to be used for cancer patients. Conclusions: The Japanese structure has clearly improved during the past 17 years in terms of equipment and its use, although a shortage of personnel and variations in maturity disclosed by Patterns of Care Study stratification were still problematic in 2007. [ABSTRACT FROM AUTHOR]

Purpose: To analyze retrospectively the results of external beam radiotherapy for clinically localized hormone-refractory prostate cancer and investigate the clinical significance of nadir prostate-specific antigen (PSA) value within 12 months (nPSA12) as an early estimate of clinical outcomes after radiotherapy. Methods and Materials: Eighty-four patients with localized hormone-refractory prostate cancer treated with external beam radiotherapy were retrospectively reviewed. The total radiation doses ranged from 30 to 76 Gy (median, 66 Gy), and the median follow-up period for all 84 patients was 26.9 months (range, 2.7–77.3 months). Results: The 3-year actuarial overall survival, progression-free survival (PFS), and local control rates in all 84 patients after radiotherapy were 67%, 61%, and 93%, respectively. Although distant metastases and/or regional lymph node metastases developed in 34 patients (40%) after radiotherapy, local progression was observed in only 5 patients (6%). Of all 84 patients, the median nPSA12 in patients with clinical failure and in patients without clinical failure was 3.1 ng/mL and 0.5 ng/mL, respectively. When dividing patients according to low (<0.5 ng/mL) and high (≥0.5 ng/mL) nPSA12 levels, the 3-year PFS rate in patients with low nPSA12 and in those with high nPSA12 was 96% and 44%, respectively (p < 0.0001). In univariate analysis, nPSA12 and pretreatment PSA value had a significant impact on PFS, and in multivariate analysis nPSA12 alone was an independent prognostic factor for PFS after radiotherapy. Conclusions: External beam radiotherapy had an excellent local control rate for clinically localized hormone-refractory prostate cancer, and nPSA12 was predictive of clinical outcomes after radiotherapy. [Copyright &y& Elsevier]

Purpose: To determine the incidence of brain atrophy and dementia after whole-brain radiotherapy (WBRT) in patients with brain metastases not undergoing surgery. Methods and Materials: Eligible patients underwent WBRT to 40 Gy in 20 fractions with or without a 10-Gy boost. Brain magnetic resonance imaging or computed tomography and Mini-Mental State Examination (MMSE) were performed before and soon after radiotherapy, every 3 months for 18 months, and every 6 months thereafter. Brain atrophy was evaluated by change in cerebrospinal fluid–cranial ratio (CCR), and the atrophy index was defined as postradiation CCR divided by preradiation CCR. Results: Of 101 patients (median age, 62 years) entering the study, 92 completed WBRT, and 45, 25, and 10 patients were assessable at 6, 12, and 18 months, respectively. Mean atrophy index was 1.24 ± 0.39 (SD) at 6 months and 1.32 ± 0.40 at 12 months, and 18% and 28% of the patients had an increase in the atrophy index by 30% or greater, respectively. No apparent decrease in mean MMSE score was observed after WBRT. Individually, MMSE scores decreased by four or more points in 11% at 6 months, 12% at 12 months, and 0% at 18 months. However, about half the decrease in MMSE scores was associated with a decrease in performance status caused by systemic disease progression. Conclusions: Brain atrophy developed in up to 30% of patients, but it was not necessarily accompanied by MMSE score decrease. Dementia after WBRT unaccompanied by tumor recurrence was infrequent. [Copyright &y& Elsevier]

Purpose: To evaluate the structure of radiation oncology in Japan in terms of equipment, personnel, patient load, and geographic distribution to identify and improve any deficiencies. Methods and Materials: A questionnaire-based national structure survey was conducted between March 2006 and February 2007 by the Japanese Society of Therapeutic Radiology and Oncology. These data were analyzed in terms of the institutional stratification of the Patterns of Care Study. Results: The total numbers of new cancer patients and total cancer patients (new and repeat) treated with radiotherapy in 2005 were estimated at approximately 162,000 and 198,000, respectively. In actual use were 765 linear accelerators, 11 telecobalt machines, 48 GammaKnife machines, 64 60Co remote-controlled after-loading systems, and 119 192Ir remote-controlled after-loading systems. The linear accelerator systems used dual-energy function in 498 systems (65%), three-dimensional conformal radiotherapy in 462 (60%), and intensity-modulated radiotherapy in 170 (22%). There were 426 Japanese Society of Therapeutic Radiology and Oncology-certified radiation oncologists, 774 full-time equivalent radiation oncologists, 117 medical physicists, and 1,635 radiation therapists. Geographically, a significant variation was found in the use of radiotherapy, from 0.9 to 2.1 patients/1,000 population. The annual patient load/FTE radiation oncologist was 247, exceeding the Blue Book guidelines level. Patterns of Care Study stratification can clearly discriminate the maturity of structures according to their academic nature and caseload. Conclusions: The Japanese structure has clearly improved during the past 15 years in terms of equipment and its use, although the shortage of manpower and variations in maturity disclosed by this Patterns of Care Study stratification remain problematic. These constitute the targets for nationwide improvement in quality assurance and quality control. [Copyright &y& Elsevier]

Purpose: To investigate in a prospective randomized study the effect of radiation fraction size and overall treatment time on the local control of early glottic carcinoma. Methods and Materials: Between December 1993 and December 2001, 180 patients with early glottic carcinoma (T1N0M0) were treated at our department. The patients were randomly allocated to either treatment arm A (radiation fraction size 2 Gy, n = 89) or B (2.25 Gy, n = 91). The total radiation dose administered was 60 Gy in 30 fraction within 6 weeks for minimal tumors (two-thirds of the vocal cord or less) or 66 Gy in 33 fractions in 6.6 weeks for larger than minimal tumors (more than two-thirds of the vocal cord) in Arm A and 56.25 Gy in 25 fractions within 5 weeks for minimal tumor or 63 Gy in 28 fractions within 5.6 weeks for larger than minimal tumors in Arm B. Results: The 5-year local control rate was 77% for Arm A and 92% for Arm B (p = 0.004). The corresponding 5-year cause-specific survival rates were 97% and 100% (no significant difference). No significant differences were found between these two arms in terms of rates of acute mucosal reaction, skin reactions, or chronic adverse reactions. Conclusion: Use of 2.25-Gy fractions with a shorter overall treatment time for Arm B showed superior local control compared with conventional use of 2-Gy fractions for Arm A without adverse reactions from the greater fraction. [Copyright &y& Elsevier]

Purpose: To evaluate the actual work environment of radiation oncologists (ROs) in Japan in terms of working pattern, patient load, and quality of cancer care based on the relative time spent on patient care. Methods and Materials: In 2008, the Japanese Society of Therapeutic Radiology and Oncology produced a questionnaire for a national structure survey of radiation oncology in 2007. Data for full-time ROs were crosschecked with data for part-time ROs by using their identification data. Data of 954 ROs were analyzed. The relative practice index for patients was calculated as the relative value of care time per patient on the basis of Japanese Blue Book guidelines (200 patients per RO). Results: The working patterns of RO varied widely among facility categories. ROs working mainly at university hospitals treated 189.2 patients per year on average, with those working in university hospitals and their affiliated facilities treating 249.1 and those working in university hospitals only treating 144.0 patients per year on average. The corresponding data were 256.6 for cancer centers and 176.6 for other facilities. Geographically, the mean annual number of patients per RO per quarter was significantly associated with population size, varying from 143.1 to 203.4 (p < 0.0001). There were also significant differences in the average practice index for patients by ROs working mainly in university hospitals between those in main and affiliated facilities (1.07 vs 0.71: p < 0.0001). Conclusions: ROs working in university hospitals and their affiliated facilities treated more patients than the other ROs. In terms of patient care time only, the quality of cancer care in affiliated facilities might be worse than that in university hospitals. Under the current national medical system, working patterns of ROs of academic facilities in Japan appear to be problematic for fostering true specialization of radiation oncologists. [ABSTRACT FROM AUTHOR]